{"name":"Ultragenyx Pharmaceutical Inc","slug":"ultragenyx-pharmaceutical-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":673000000,"revenueGrowth":20.1,"grossMargin":0,"rdSpend":750000000,"netIncome":-575000000,"cash":1532000000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"Adjuvant IM Therapy","genericName":"Adjuvant IM Therapy","slug":"adjuvant-im-therapy","indication":"Other","status":"phase_2"},{"name":"Antipyretic","genericName":"Antipyretic","slug":"antipyretic","indication":"Other","status":"phase_3"},{"name":"GTX-102","genericName":"GTX-102","slug":"gtx-102","indication":"FUS-associated amyotrophic lateral sclerosis (ALS)","status":"phase_3"},{"name":"Mepsevii","genericName":"Mepsevii","slug":"mepsevii","indication":"Mucopolysaccharidosis, MPS-VII","status":"marketed"},{"name":"Placebo for oral corticosteroids","genericName":"Placebo for oral corticosteroids","slug":"placebo-for-oral-corticosteroids","indication":"Control arm in Phase 3 trial for oral corticosteroid-dependent condition (specific indication unknown)","status":"phase_3"},{"name":"Reactive Corticosteroid Taper Regimen","genericName":"Reactive Corticosteroid Taper Regimen","slug":"reactive-corticosteroid-taper-regimen","indication":"Other","status":"phase_1"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"UX003","genericName":"UX003","slug":"ux003","indication":"Hypercholesterolemia","status":"phase_3"}]}],"pipeline":[{"name":"UX003","genericName":"UX003","slug":"ux003","phase":"phase_3","mechanism":"UX003 is a recombinant human monoclonal antibody that targets angiopoietin-like 3 (ANGPTL3) protein.","indications":["Hypercholesterolemia"],"catalyst":""},{"name":"Adjuvant IM Therapy","genericName":"Adjuvant IM Therapy","slug":"adjuvant-im-therapy","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Antipyretic","genericName":"Antipyretic","slug":"antipyretic","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GTX-102","genericName":"GTX-102","slug":"gtx-102","phase":"phase_3","mechanism":"GTX-102 is an antisense oligonucleotide that reduces production of FUS protein by targeting FUS mRNA in patients with FUS-associated neurological disease.","indications":["FUS-associated amyotrophic lateral sclerosis (ALS)","FUS-associated frontotemporal dementia (FTD)"],"catalyst":""},{"name":"Mepsevii","genericName":"Mepsevii","slug":"mepsevii","phase":"marketed","mechanism":"Small molecule","indications":["Mucopolysaccharidosis, MPS-VII"],"catalyst":""},{"name":"Placebo for oral corticosteroids","genericName":"Placebo for oral corticosteroids","slug":"placebo-for-oral-corticosteroids","phase":"phase_3","mechanism":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","indications":["Control arm in Phase 3 trial for oral corticosteroid-dependent condition (specific indication unknown)"],"catalyst":""},{"name":"Reactive Corticosteroid Taper Regimen","genericName":"Reactive Corticosteroid Taper Regimen","slug":"reactive-corticosteroid-taper-regimen","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPR1FuQWN1bEJnZ2RnUkVuNnJ6MVBNRWR6OEpTWU4tbmp5VUc2NnJSVUZyZzRRRDVHM1VnLWpFdjRBUDdRaGppUUh2OVd5bGtGZGIzRlY2dktMR1VOWUgwQ3NuUzgwcGNxa2hPOFk2NEQzYXpiUHRBaUJwNzhVMXU4S0lsMXBncUg4NDlEZEtGYzJNQUlvRlJQRVdJel9icTQzcGF5eGQ2T2ZlWWxTYThhczJoemRwUzhZZEtlMkVn?oc=5","date":"2026-04-06","type":"regulatory","source":"TradingView","summary":"RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome - TradingView","headline":"RARE Rises as FDA Accepts Resubmitted BLA for Sanfilippo Syndrome","sentiment":"neutral"},{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTFBvRDdtczZUNW1zakZtM25BWUFUOEt5TDlUZFJudWI1ZUx3T2xKbk4yaTk2SVVmNlUyT1dGUGdxbnBNZURxMnRpbFcxSGI4TUhWejZyZlR5N1BsSXZ1bmfSAWNBVV95cUxPWjFleGc2R2hmT0tUd2ZBV0IxV0M3VXVNaTMzWl9jSm1WaHZPaXQ5TnNNeXk3RnRPbEJJR1JMblFFeVZaLUpYS3pVdndBaDhad3A5VjJsd0duOUVWQVBIdVVkX0E?oc=5","date":"2026-03-31","type":"regulatory","source":"Bitget","summary":"Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016 - Bitget","headline":"Ultragenyx Pharmaceutical Reports FDA Acceptance of IND Application for UX016","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPNjZ6Y0ZkdHFTR0hCdlJDSGN6WkI1bktNV1puV3lFX1F6RzZjY2o4MDBwb09VMU5tUkRBTmJBRzliZnBtOC1vbUY4NlRYYzg0NnFhQnhkMTF4VU5fUG1Hd1c4MHBtbGJfQUJhYUhFc25mbEtDOWFKMDlHaU1ZWGtPbGdiWmhza09ZOHY5bFVyVTFEZHV1ckhUWEdVeU5leVdUaGFJWmY3Qk1JYnBtMGVCRTR5amkzdGRlcnlr?oc=5","date":"2026-03-31","type":"regulatory","source":"TradingView","summary":"Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND - TradingView","headline":"Ultragenyx Pharmaceutical Announces FDA Acceptance of UX016 IND","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNd0tJX1JoVVZVdDltcDdqSlp0aExUV004U2FWeXNjeHcwMXVhbG9Uc0ZYOTRkVnpLcmdOWGNtcXNibWdrZFl2ZWZxeEZURDY0ZlJFZmtsdnZoN09oZjhGRUlBSUhOVFJrSlktMnRtbnNfYU5yNFhKVXVuRmVKNWt4cUIwNEpkM1FOZmZXQ1JlWV9WQnFyeGI5dW1jS3p3YkVRYUJGVThKUERRTU1FLUNuRi1pcERublNKemZHdEF3UjNXbG9XWXlZLWY1aGR3RnE3TlBLS29KNzd5NERHZnF3UFIxRG9CZy0ySmprVmNmdnhGLXJFOGdwakp6c0hucHR3ZFFWb1JyQ1BlODdJMHV5eE5qSU8tYng4bVp5VEdSX0Y3Z09IanJlZTQxcTlwZw?oc=5","date":"2026-03-26","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Alnylam Pharma (ALNY) and Ultragenyx Pharmaceu","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZnF5TndKV3RYb2JMYWg3aDlKNUhrakllZ1hoWWk0b0k5ZndVQU1VWjMxRTlLdE56YTh3MURfMzFHcmtOUE93VXdZQkozRExLZmxOSHpydU0tWENrXzVZWkJpRDhFNGEtMGc0LTJUZmtmTW9qeTdZcHJ6dkhUMExlVERsLWpnZC1XVHRMbnhDT2hkVjZ0UmhrMWw1T28waXh3YjV0bE9iR2YyVzh5UTFicEhwOEFIbE9maVRlQUFHdnNmQQ?oc=5","date":"2026-01-27","type":"pipeline","source":"Investing.com","summary":"Barclays reiterates Overweight rating on Ultragenyx Pharma stock - Investing.com","headline":"Barclays reiterates Overweight rating on Ultragenyx Pharma stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxOWjlQVmNBbVBsTlNiYzQ5R1dvanUyZjB3ZDZGUjIxWDBnWXBpWGRUbHItakl5eGFUWkpRTW5CVmJGRTZEa0ViSTZJVW5DMlB2VjFGYWxwcG9ZbEEyTjlKOWlTbXQzTHdOLXB0WFBLMFVXN0p6QllFdjhvVVlBdHhKRW9RSW5YbFU5djM3UjF0VTh4dEc4U2k3cmhKYWNmdnVyby1XclF4TGVEaV9Sci1HX2UwN3ljQkE0OWpuLWJwYlUwWVNYTGFz?oc=5","date":"2026-01-04","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures - Genetic Engineering and Biotechnology News","headline":"StockWatch: Ultragenyx, Mereo Plummet on Brittle Bone Candidate Failures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPbElDeDZnc1M5R2o3d216S2FBekFDQ0FPcE5fTDhQU1ZIZ1VCUVVDQXdSX2F3UFN3Q2xxSkVHdmF4eGtGWlVCUWlWMG9hY0g4NUNnZlZQbkVFWXZQYjFHanR0TlR5ZXdNTDdnNlNkNVFPdEJ6SEF6RnVXTHJGREEzRHhnWEotVFBZbnE3OTRHNlljSGgySlJEd25fdG4wSnhrZjNkWEdxcFM4aFRUaVpMd05n?oc=5","date":"2025-12-30","type":"trial","source":"The Pharma Letter","summary":"Ultragenyx and Mereo tank as Phase III setrusumab trial disappoints - The Pharma Letter","headline":"Ultragenyx and Mereo tank as Phase III setrusumab trial disappoints","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOWExuVlhCRVliVlkya18xRkVTbEk3amJnNEJPMkNjcEJSTlVmOUg3dlQ4QUVMdV9UcVQ2SDdEY2l0eDVjYUNSTERheURlWlI3bFVmaksyZFB0LUVYRzVJWlg2V25ydzcxU2ttc0dWQTR2aEJWaEpqc3VOd3o1eHlwNTdObk92Nkp3Q3FId1g4V3RPbzEzbWI4WA?oc=5","date":"2025-12-29","type":"pipeline","source":"The Motley Fool","summary":"Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today - The Motley Fool","headline":"Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWDBNcU9sQy1HRW5jMFFTbjE4WjU2NklsZnNaNmFOaHBkcEtCbTdSWXV1eEZ0ckNLQmloMmxqMHJDT0R6OVEzbUJmNkpqdHFmR0huSmhVdzRldnBTY2dMWlFTZUF2dWtCYl81TGdfYlk5SENBbUdxVXZ1YThqYnFtR1dpS2huazhDYkJZWEYyTWpYV3hCdGVkTlctOEoyMERXNzlVVVhrRng1TUdlRnhQbHlNQzJvMGlhMWc0U0U0bDBiZ1U?oc=5","date":"2025-12-29","type":"pipeline","source":"Reuters","summary":"Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate - Reuters","headline":"Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQanVrRGFsY2dvVFlELURiLW5OLVBDQVhPbUhjNGVmanh0UnF6RWd2RU44ZHpPVGcxVkhmSG9BaW9GN3lfd0NCTzVYQmZ6MWlUckV4YURkMExzZW1DX183TjlLMUJpdXBESjJtdjh4ZXBJMnYyOTdYWTdBajhiLW9WczBUU2ZhV3VrSFBaUWpTZUpxa1VTeDlKY01sai1ZeFBleFdzTUlTVzRfUlctRGhuT09ERmZnaXMzNnJ2bHZaQ3RobkI0aTJHUUpFc2V2eFFKZmk1Q1RuMWh0YTdVd1E?oc=5","date":"2025-12-29","type":"trial","source":"Investing.com","summary":"Ultragenyx Pharma stock steady as Truist reiterates Buy rating despite trial setbacks - Investing.com","headline":"Ultragenyx Pharma stock steady as Truist reiterates Buy rating despite trial setbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNUWlPU2pFcU5fbno3cm5RR05nY2ZrSUZWTkNqbDY4VUVLWU8zSjRyMDE4LXZuYk01WTVhNEpkVUdOMVpET2YwUXZXVGstYklQV0ZoSXR3aUNfeVp4LURvR203ZnRuQ0ZzVlBuRXZOYVBYUFRwa1Z0d3J3R1RXMEtGRk5oRm1NRnFXaFU2enBEMVZTYlE1X0NITEdBSDloNmdycVJuNXMtWGc3UzB3a1RXSmtwMjVDaXIzZEo5QkdZQTQzcXdlRHppLWdCNDJ1MWtaamVrS2FWX0RLUQ?oc=5","date":"2025-07-11","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - Reuters","headline":"US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQRF9VcGtnQXdmVG5oOXI5UXpCNWJwQ2RCT0hWLVZCakxxQ1FONnpudGcxa1FGV3U3YnJESzhVTW1tOUFibHAwdVdFbTFUdHZYck9qUmJ0ZnBybFFvcGFRZWxnMWJWTHlZMUR0Xy1neldiMXZ4bzB3RWdqUWhycWl2SmVLVFBJUDhvZl9aRXpDdnJzM25RYlhpZDk4U0poSVZOQ19qMlJnR24wc2tuMmVUV1p2UXlIY00?oc=5","date":"2025-07-10","type":"trial","source":"Seeking Alpha","summary":"Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss (RARE) - Seeking Alpha","headline":"Ultragenyx: 'Hold' The Best Strategy As Stock Tanks On Bone Disease Study Miss (RARE)","sentiment":"negative"}],"patents":[],"drugCount":7,"phaseCounts":{"phase_3":4,"phase_2":1,"marketed":1,"phase_1":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":673000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":673000000,"period":"2025-12-31"},{"value":560230000,"period":"2024-12-31"},{"value":560000000,"period":"2024-12-31"},{"value":434249000,"period":"2023-12-31"},{"value":434249000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":750000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-575000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1532000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}